These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1599 related articles for article (PubMed ID: 28303724)

  • 21. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation.
    Farzanegi P; Dana A; Ebrahimpoor Z; Asadi M; Azarbayjani MA
    Eur J Sport Sci; 2019 Aug; 19(7):994-1003. PubMed ID: 30732555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systems-level organization of non-alcoholic fatty liver disease progression network.
    Shubham K; Vinay L; Vinod PK
    Mol Biosyst; 2017 Aug; 13(9):1898-1911. PubMed ID: 28745372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
    Sun C; Fan JG; Qiao L
    Int J Mol Sci; 2015 Mar; 16(3):5161-79. PubMed ID: 25751727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
    Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease.
    Arias-Loste MT; Iruzubieta P; Puente Á; Ramos D; Santa Cruz C; Estébanez Á; Llerena S; Alonso-Martín C; San Segundo D; Álvarez L; López Useros A; Fábrega E; López-Hoyos M; Crespo J
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic Transporters Alternations Associated with Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review.
    Omidkhoda N; Zare S; Mahdiani S; Samadi S; Akhlaghi F; Mohammadpour AH
    Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):1-10. PubMed ID: 36319903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
    Yilmaz Y
    Aliment Pharmacol Ther; 2012 Nov; 36(9):815-23. PubMed ID: 22966992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beverage consumption and paediatric NAFLD.
    Mosca A; Della Corte C; Sartorelli MR; Ferretti F; Nicita F; Vania A; Nobili V
    Eat Weight Disord; 2016 Dec; 21(4):581-588. PubMed ID: 27565159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
    Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
    Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoids and non-alcoholic fatty liver disease.
    Woods CP; Hazlehurst JM; Tomlinson JW
    J Steroid Biochem Mol Biol; 2015 Nov; 154():94-103. PubMed ID: 26241028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations.
    Adinolfi LE; Rinaldi L; Guerrera B; Restivo L; Marrone A; Giordano M; Zampino R
    Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27231906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease.
    Dietrich CG; Rau M; Jahn D; Geier A
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):625-640. PubMed ID: 28359183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
    Zhuge B; Li G
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality.
    Brouwers MCGJ; Simons N; Stehouwer CDA; Isaacs A
    Diabetologia; 2020 Feb; 63(2):253-260. PubMed ID: 31713012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron and non-alcoholic fatty liver disease.
    Britton LJ; Subramaniam VN; Crawford DH
    World J Gastroenterol; 2016 Sep; 22(36):8112-22. PubMed ID: 27688653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
    Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
    Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.